At the same time, the combination therapy of CARM1 inhibitor TP064, a vital regulator of the BAF complex, and P53 agonist Nutlin-3 also provides a potentially effective treatment option for GC patients with ARID1A mutation [44]. This evidence concerns the gene TP53 and gastric cancer.